Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

UNITED: A Unified Transparent and Efficient Phase I/II Trial Design for Dose Optimization Accounting for Ordinal Graded, Continuous and Mixed Toxicity and Efficacy Endpoints

Statistics in Medicine(2025)10.1002/sim.70098Source: DataRank Database

UNITED: A Unified Transparent and Efficient Phase I/II Trial Design for Dose Optimization Accounting for Ordinal Graded, Continuous and Mixed Toxicity and Efficacy Endpoints is a research paper published in Statistics in Medicine (2025). On theSindex it has a DataRank of 0. It has been cited 3 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access3 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (2 grants)Impact (FWCI 4.30)OA: hybridTopics (48)IDs (PubMed, PMC, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (3)

Zhonglong Guo ORCID,Yingjie Qiu ORCID,Mingyue Li ORCID

Live enrichment

PubMed:40384182 PMC:PMC12086506 OpenAlex:https://openalex.org/W4410507193

National Cancer Institute

Grant: P30CA142543

National Institutes of Health

Grant: 3P30CA142543-12S1

Multidimensional single-cell approach probing HIV-1 integration association with non-AIDS defining cancers (Biospecimens/Biocohort)

FWCI

4.30

Citation Percentile

0.9%

Citation Trend

2025

2026

hybridLicense: cc-by-nc-nd

journalhttps://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/sim.70098

publisherhttps://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/sim.70098

publisherhttps://onlinelibrary.wiley.com/doi/pdf/10.1002/sim.70098

journalhttps://doi.org/10.1002/sim.70098

repositoryhttps://pubmed.ncbi.nlm.nih.gov/40384182

Fields of Study

Statistical Methods in Clinical TrialsOptimal Experimental Design MethodsHealth Systems, Economic Evaluations, Quality of Life

MeSH Terms

Antineoplastic AgentsComputer SimulationDose-Response Relationship, DrugHumansResearch DesignUnited StatesModels, StatisticalTreatment OutcomeClinical Trials, Phase I as TopicClinical Trials, Phase II as TopicMaximum Tolerated DoseEndpoint Determination

Keywords

Maximum tolerated doseToxicityLimitingClinical trialClinical endpointMedicineClinical study designClinical efficacyResearch designComputer scienceMedical physicsPharmacologyInternal medicineStatisticsMathematicsEngineeringAdaptive DesignPhase I/ii TrialOptimal Biological DoseToxicity GradesDelayed OutcomesEfficacy GradesClinical Trials, Phase II as TopicModels, StatisticalTreatment OutcomeClinical Trials, Phase I as TopicDose-Response Relationship, DrugEndpoint DeterminationHumansComputer SimulationAntineoplastic AgentsUnited StatesResearch Article

Sustainable Development Goals

SDG 0: Partnerships for the goals